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SUMMARY
Background
The use of non-steroidal anti-inflammatory drugs (NSAIDs) is often
associated with upper gastrointestinal symptoms such as heartburn and
acid regurgitation.
Aim
To assess the efficacy of esomeprazole 20 and 40 mg for resolution of
heartburn and acid regurgitation in continuous NSAIDs.
Methods
A post hoc analysis of five clinical trials was performed. Two identically
designed, placebo-controlled, 4-week studies (NASA1, SPACE1) enrolled
non-ulcer, NSAIDs-treated patients with upper abdominal pain, dis-
comfort or burning. PLUTO and VENUS were identically designed,
placebo-controlled, 6-month studies that enrolled patients at risk of
NSAIDs-induced ulcers. Study 285 was an 8-week comparative study with
ranitidine (300 mg/day) in patients with NSAIDs-induced gastric ulcers.
Resolution of investigator-assessed heartburn and acid regurgitation was
defined as symptom severity of ‘none’ in the last 7 days.
Results
In NASA1/SPACE1, heartburn resolved in 61% and 62% of patients
taking esomeprazole 20 and 40 mg, respectively (vs. 36% on placebo,
P < 0.001), and acid regurgitation resolved in 65% and 67% (vs. 48%,
P < 0.001). Resolution of both symptoms was greater with esomeprazole
than with placebo in PLUTO/VENUS (P £ 0.001), and than with raniti-
dine in study 285 (P < 0.05 for esomeprazole 20 mg).
Conclusion
Heartburn and regurgitation are common in patients taking NSAIDs and
esomeprazole is efficacious for resolution of these symptoms.
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are
widely prescribed to treat arthritic disorders and to
manage pain and inflammation in a variety of other
conditions.1, 2 Although NSAIDs are effective in the
treatment of inflammatory conditions, their use has
been shown to increase the incidence of gastric
mucosal damage and upper gastrointestinal (GI) symp-
toms.3–6 Cyclooxygenase (COX)-2-selective NSAIDs
were developed for their ability to circumvent the
effects on the GI mucosa and ulcer development,6 but
the benefit of COX-2 inhibitors over non-selective
NSAIDs appears to be less substantial in relation to
upper GI symptoms.7–10
Upper GI symptoms that may occur during NSAID
therapy include dyspepsia, heartburn, acid regurgita-
tion and nausea. In an attempt to minimize the effects
of such symptoms among NSAID users, physicians
may opt to reduce the dose,11 and thus risk recurrence
of the underlying inflammatory condition. Another
clinically appropriate option would be effective pre-
vention or treatment of upper GI symptoms to facili-
tate well-tolerated administration of NSAID therapy at
the most appropriate dose.
Although NSAID-induced upper GI injury may, in
part, be pH dependent,12 the mechanisms underlying
concomitant upper GI symptoms are not as well
understood. Symptoms may potentially be caused by
microscopic injury or exacerbation of underlying con-
ditions, such as gastro-oesophageal reflux disease
(GERD).13 However, as acid-suppressive therapy with a
proton pump inhibitor (PPI) has been shown to
improve upper GI symptoms in chronic NSAID users
with or without gastroduodenal lesions,14–16 it is poss-
ible that symptoms are related to gastric acidity.
We aimed to assess the efficacy of esomeprazole
therapy for treatment of heartburn and acid regurgi-
tation in continuous users of NSAIDs, including
COX-2-selective agents. This post hoc analysis
comprised five large, randomized, double-blind,
multicentre clinical trials.16–18 Two of the studies
(NASA1/SPACE1) evaluated esomeprazole for relief
of upper abdominal pain, discomfort or burning in
non-ulcer populations who did not have a prior his-
tory of GERD or dyspepsia.16 Another two studies
(PLUTO/VENUS) investigated esomeprazole for the
prevention of NSAID-associated peptic ulcer in
at-risk patients.17 Study 285 assessed healing of
NSAID-associated gastric ulcers with esomeprazole.18
PATIENTS AND METHODS
Patients on continuous NSAID therapy, including
COX-2-selective agents, were enrolled into various
randomized, double-blind multicentre studies (Figure 1).
Patients entering these studies were Helicobacter
pylori-negative and were expected to require stable,
continuous NSAID therapy for the duration of the
trials. All studies were approved by independent ethics
committees and were performed in accordance with
the principles of the Declaration of Helsinki. All
patients provided written informed consent.
Studies in non-ulcer patients with baseline pain,
discomfort or burning in the upper abdomen
(NASA1/SPACE1)
Two identical placebo-controlled studies [NASA1
(ClinicalTrials.gov Identifier: NCT00241540, study code:
SH-NEN-0001) and SPACE1 (ClinicalTrials.gov Identi-
fier: NCT00241527, study code: SH-NEN-0003)]
enrolled patients with pain, discomfort or burning in
the upper abdomen who had been taking stable, con-
tinuous NSAID treatment for ‡4 weeks prior to baseline
endoscopy and whose treatment was expected to con-
tinue for ‡7 months (i.e. the duration of these and the
subsequent maintenance studies). Treatment could
include COX-2-selective agents, non-selective NSAIDs,
high-dose aspirin (>325 mg/day), or a combination of
any of these.16 Continuous NSAID treatment was
defined as medication use on ‡5 days in any given week
for at least 4 weeks prior to screening. Patients who
reported pain, discomfort or burning of at least moder-
ate severity [score of ‡3 on a 7-point scale,19 where
0 ¼ none and 6 ¼ very severe] on at least 3 days of the
screening week prior to the study were randomized to
treatment with esomeprazole 20 or 40 mg once daily or
matching placebo. Patients were excluded if they had a
history of dyspepsia or GERD not associated with NSAID
use (based on patient recall), as were those with current
or previous gastroduodenal ulcer or erosive oesophagi-
tis. The primary objective of these studies was to assess
the efficacy of esomeprazole for the relief of pain, burn-
ing or discomfort in the upper abdomen; these results
are reported elsewhere.16
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Studies in patients at increased risk of gastric
ulcers (PLUTO/VENUS)
Two identical placebo-controlled studies [PLUTO
(study code: SH-NEN-0013) and VENUS (study code:
SH-NEN-0014)] assessed the efficacy of esomeprazole
20 or 40 mg once daily for preventing gastric ulcers
in at-risk patients (‡60 years old and/or a history of
gastric or duodenal ulcers in the past 5 years) taking
continuous NSAID therapy.17 NSAID therapy must
have been stable during the 4 weeks before baseline
endoscopy, and was to remain stable throughout the
study. Patients had no gastric or duodenal ulcers or
evidence of oesophagitis detectable by endoscopy at
baseline. Patients with evidence of oesophagitis,
oesophageal stricture or Barrett’s oesophagus were
excluded.
Study in patients with gastric ulcers (Study 285)
Study 285 (study code: SH-NEN-0005) assessed the
efficacy of esomeprazole 20 or 40 mg once daily vs.
ranitidine 150 mg b.d. for healing NSAID-associated
gastric ulcers.18 Patients were required to be taking
daily NSAID treatment (defined as ‡5 days/week) at a
stable prescribed dose for a minimum of 4 weeks
before baseline endoscopy. NSAID treatments could
include COX-2-selective agents, multiple NSAIDs, or
aspirin at doses of ‡80 mg/day. Patients were to have
at least one NSAID-related gastric ulcer ‡5-mm diam-
eter, but no gastric or duodenal ulcer >25-mm diam-
eter, at baseline. Patients were excluded if they had
current or historical evidence (within 3 months) of
malabsorption, oesophageal stricture, oesophagitis or
Barrett’s oesophagus.
Assessments
This post hoc analysis assessed the efficacy of esomep-
razole for the relief of NSAID-associated heartburn
and acid regurgitation in these five studies. In all stud-
ies, heartburn was defined as ‘a burning feeling, rising
from the stomach or lower part of the chest towards
the neck’ and acid regurgitation was defined as ‘flow
of sour or bitter fluid into the mouth’. Investigators
assessed the severity of patients’ heartburn and acid
regurgitation symptoms during the past 7 days using a
4-grade scale (where 0 ¼ none, 1 ¼ mild, 2 ¼ moderate
and 3 ¼ severe) validated for the assessment of heart-
burn severity in symptomatic GERD patients.20
Responsiveness of the 4-point scale was previ-








































Figure 1. Study designs of the
NASA1/SPACE1, PLUTO/
VENUS, and 285 studies.
* Patients initially diagnosed
Helicobacter pylori-negative at
baseline, who were then found
to be H. pylori-positive by his-
tological analysis, were inclu-
ded in the studies. b.d., twice
daily; Eso, esomeprazole;
NSAID, non-steroidal anti-
inflammatory drug; R, rand-
omization.
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questionnaire as an anchor. The scale correlated well
with the GI Symptom Rating Scale, both for investi-
gator- and for diary-assessed heartburn severity, and
demonstrated good construct validity, responsiveness
and reliability.20
The timing of investigator assessments was pro-
spectively defined in each individual study. Assess-
ments were made at 2 and 4 weeks in the NASA1
and SPACE1 studies, at months 1, 3 and 6 in the
PLUTO and VENUS studies, and at 4 and 8 weeks in
study 285. Resolution of heartburn and acid
regurgitation was defined as a severity score of
‘none’ in the week preceding assessment. Only
patients with heartburn or acid regurgitation at
baseline were included in this analysis. Patients from
the PLUTO, VENUS and 285 studies were included in
this analysis regardless of whether they had also
experienced heartburn or acid regurgitation when
not taking NSAIDs. Patients were excluded from the
NASA1 and SPACE1 studies if they had a history of
GERD when not taking NSAIDs. To assess the effect
of COX-2-selective NSAIDs on heartburn and acid
regurgitation in the NASA1 and SPACE1 studies,
patients were included in the COX-2-selective
subpopulations only if they were using a COX-2-
selective agent with no other NSAID or aspirin.
Statistical analysis
In patients eligible for analysis (i.e. with heartburn
or acid regurgitation at baseline), differences between
treatment groups in each study were analysed by
using Fisher’s exact test. Number needed to treat to
avoid persistent heartburn or acid regurgitation dur-
ing NSAID therapy was calculated as the inverse of
absolute risk reduction for the different populations
(non-ulcer patients who are taking NSAIDs and who
have upper abdominal pain, burning or discomfort,
patients at risk of developing NSAID-associated
ulcers, and patients with NSAID-associated gastric
ulcers). The 95% CI were also calculated.
RESULTS
Baseline demographic and clinical characteristics of
the study populations are shown in Table 1. The pre-
valence of heartburn and acid regurgitation was high-
est in the NASA1/SPACE1 population, with 87% of
patients reporting some degree of heartburn, as
assessed by the investigator, and 77% having acid
regurgitation. In each study, the prevalence of heart-
burn and acid regurgitation was similar between
treatment groups. The mean age was higher in the
PLUTO/VENUS study population, while the use of
COX-2-selective agents was lowest in study 285. For
all studies, resolution rates refer only to patients who
had the symptom at baseline.
Non-ulcer patients with baseline pain,
discomfort or burning in the upper abdomen
(NASA1/SPACE1)
In these studies, both doses of esomeprazole (20 or
40 mg once daily) were significantly more effective
than placebo for resolution of heartburn and acid
regurgitation after 4 weeks of treatment (Figure 2).
Table 1. Baseline demographic
and clinical characteristics
of patients in the NASA1/
SPACE1, PLUTO/VENUS,









Sex,% women 75 71 71
Mean age (year) 55 65 58
Type of chronic condition, %:
Rheumatoid arthritis 21 19 11
Osteoarthritis 42 65 58
Other 37 16 31
Heartburn at baseline, % 87 50 69




COX-2-selective NSAID use, % 34 29 19
NSAID, non-steroidal anti-inflammatory drug.
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Moreover, esomeprazole was significantly more effect-
ive than placebo for resolution of heartburn and acid
regurgitation in users of non-selective and COX-2-
selective NSAIDs (Table 2).
Patients at increased risk of ulcers (PLUTO/
VENUS)
Among continuous NSAID users at increased risk of
peptic ulcer development, esomeprazole at either dose
(20 or 40 mg once daily) was significantly more
effective than placebo for resolution of heartburn
and acid regurgitation after 6 months of treatment
(Figure 3).
Patients with gastric ulcers (Study 285)
Among patients with NSAID-associated gastric ulcer
who, at baseline, also had heartburn or acid regurgita-
tion, esomeprazole 20 and 40 mg once daily was more
effective than ranitidine 150 mg b.d. for symptom
resolution after 8 weeks of treatment (Figure 4).
Numbers needed to treat
The numbers needed to treat with esomeprazole to
prevent persistent heartburn and acid regurgitation
among continuous NSAID users are shown in Table 3,
alongside the absolute risk reductions. These values
indicated that, in the population of non-ulcer patients
with epigastric pain, discomfort or burning in the
upper abdomen at baseline, no more than six patients
(range: 3–11 patients based on the 95% CI for the
absolute risk reduction) would need to be treated with
esomeprazole to avoid 1 case of persistent heartburn
or acid regurgitation during NSAID therapy that would
otherwise occur if symptoms were treated with pla-
cebo. In the population at risk for ulcer development,
the corresponding number of patients was 5 (range:
3–12). Additionally, no more than seven patients
(range: 3–188) would need to be treated with esomep-


























Figure 2. Patients in the NASA1/SPACE1 population
achieving resolution of heartburn or acid regurgitation
after 4 weeks of treatment, as a proportion of those hav-
ing either symptom at baseline. *** P < 0.001 vs. placebo.
Table 2. Patients in the NASA1/SPACE1 population achieving resolution of heartburn or acid regurgitation, by non-





resolution at week 4 (%) P-value
Heartburn COX-2-selective Placebo 39/114 (34) –
Esomeprazole 20 66/102 (65) <0.001
Esomeprazole 40 79/112 (71) <0.001
Non-selective Placebo 75/205 (37) –
Esomeprazole 20 123/207 (60) <0.001
Esomeprazole 40 116/201 (58) <0.001
Acid regurgitation COX-2-selective Placebo 43/93 (46) –
Esomeprazole 20 57/88 (65) <0.05
Esomeprazole 40 69/95 (73) <0.001
Non-selective Placebo 93/193 (48) –
Esomeprazole 20 122/187 (65) 0.001
Esomeprazole 40 113/175 (65) <0.005
COX-2, cyclooxygenase-2
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regurgitation that would otherwise occur if patients
with gastric ulcers were treated with ranitidine.
DISCUSSION
A substantial proportion of patients receiving continu-
ous NSAID therapy experienced symptoms of heart-
burn and acid regurgitation in the three study
populations analysed, which is consistent with previ-
ous observations.7, 21 The results of the current analy-
sis show that esomeprazole is effective for the
resolution of such symptoms in these patient sub-
groups, who represent a spectrum of NSAID-associated
disorders: continuous NSAID users without endoscopi-
cally evident mucosal damage in the oesophagus but
with symptoms of pain, discomfort or burning in the
upper abdomen; continuous NSAID users at risk of
peptic ulcer development; and patients with current
NSAID-associated gastric ulcers.
Heartburn and acid regurgitation were most com-
mon in the combined NASA1/SPACE1 study popula-
tion, occurring in 77–87% of patients. The NASA1/
SPACE1 population was free of peptic ulcers and
oesophagitis and had no history of heartburn or acid
regurgitation when not receiving NSAIDs, thereby
suggesting that these symptoms were occurring as a
consequence of NSAID therapy. The PLUTO/VENUS
population comprised patients at risk of ulcer develop-
ment, many of whom were ‡60 years old. This popula-
tion is likely to be broadly representative of a general
population of patients on NSAID therapy, most of
whom are elderly.22 These patients were, on average,
10 years older than those in the NASA1/SPACE1 pop-
ulation but had less heartburn and acid regurgitation.
Although this may reflect different entry criteria, it is
possible that the decreased oesophageal pain sensitiv-
ity in more elderly patients that has been postulated
previously23 played a role.
Use of COX-2-selective agents is associated with a
lower risk of GI events and drug-related discontinua-
tions compared with non-selective NSAIDs.6, 9 Indeed,
fewer patients with gastric ulcers in study 285 used
COX-2-selective agents compared with the non-ulcer
patients in NASA1/SPACE1 and PLUTO/VENUS (19%
vs. 34% and 29%, respectively). However, results from
our studies are consistent with previous observations
that, while the comparative risk of ulcers is less in
patients using COX-2 inhibitors than in patients
receiving non-selective NSAIDs, the two classes are
less differentiated in terms of upper GI symp-
toms.7, 8, 10 In the pooled NASA1/SPACE1 patient
population, the relatively high proportion of patients
using COX-2-selective agents, and the high propor-
tions of patients with heartburn and acid regurgitation
at baseline, facilitated meaningful comparisons by
NSAID type. In this analysis, a similar proportion of
placebo recipients experienced persistent symptoms of
heartburn and acid regurgitation regardless of whether
they were using COX-2-selective agents or non-
selective NSAIDs, as has been reported for the end-

























145n = 188 200 119 148156
Figure 3. Patients in the PLUTO/VENUS population
achieving resolution of heartburn or acid regurgitation
after 6 months of treatment, as a proportion of those hav-


























85n = 94 87 64 6264
Figure 4. Patients in the 285 study achieving resolution
of heartburn or acid regurgitation after 8 weeks of treat-
ment, as a proportion of those having either symptom at
baseline. * P < 0.05 vs. ranitidine 150 mg b.d.
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It is of note that this analysis only included patients
with symptoms of heartburn and acid regurgitation at
baseline. As these patients were a subgroup of the
entire patient populations randomized in the respective
studies, the population for analysis may be influenced
by systematic bias. This analysis included all patients
with heartburn and acid regurgitation at baseline,
regardless of whether their symptoms were exclusively
NSAID-associated or not. In an effort to exclude
patients with heartburn and acid regurgitation not
associated with NSAIDs, patients with a history of
GERD when not taking NSAIDs (based on patient
recall) were excluded from the NASA1/SPACE1 stud-
ies. However, this was not an exclusion criterion for
the PLUTO/VENUS and 285 studies. Therefore, while
symptoms of heartburn and acid regurgitation in the
NASA1/SPACE1 populations are unlikely to be directly
attributable to GERD, this may have been a confound-
ing factor in the PLUTO/VENUS and 285 studies,
meaning that some patients in these studies may have
had NSAID-independent GERD. In addition, given the
high prevalence of GERD in the general population, it
is also possible that some patients’ symptoms may
have been due to the presence of occult GERD. By the
same token, however, it can pragmatically be argued
that our data do represent patients with NSAID-associ-
ated GERD. Another potential limitation is that symp-
tom history when not taking NSAIDs was based
exclusively on patient recall. It is possible that this
may have been inaccurate in patients who had been
taking NSAID medication for a long period of time.
The associative mechanisms of NSAID use and
upper GI symptomatology are not fully understood.
NSAIDs have multiple effects on GI biology that
may act in concert to compromise mucosal defence
and potentiate acid-related symptoms. For example,
reduction in prostaglandin levels resulting from COX
inhibition by NSAIDs compromises the barrier that
protects the gastric mucosa from acid damage;24, 25
the extent to which analogous effects occur in the
oesophagus, however, is not clear. NSAIDs have
been observed to cause increased gastric acidity,26, 27
which could contribute to the upper GI symptoms
that may occur with such therapy. Altered motility
could also potentially be responsible, but the effects
of NSAIDs on gastro-oesophageal sphincter function
and gastric emptying have been little studied and
results are inconsistent.28, 29 Thus, direct and indirect
mucosal injury may be implicated in the develop-
ment of some symptoms, and it is possible that the
increased gastric acidity associated with NSAIDs
results in increased oesophageal acid exposure and
associated symptoms of heartburn and acid regurgi-
tation. The finding that NSAID-associated symptoms
of heartburn and acid regurgitation were resolved
with esomeprazole therapy indicates that these
symptoms are likely to be acid-related.
A dose–response relationship was not observed
between esomeprazole 20 and 40 mg in terms of reso-
lution rates for the entire NSAID population. Although
a slight dose–response relationship was observed for
the COX-2 subpopulation, this was not significant.
Table 3. Absolute risk reduction and number needed to treat to avoid patients having persistent heartburn or acid regurgi-
tation after 4 weeks (NASA1/SPACE1), 8 weeks (285) or 6 months’ (PLUTO/VENUS) treatment with esomeprazole relative to









NASA1/SPACE1 (placebo) Heartburn Esomeprazole 20 0.25 (0.18–0.33) 4 (3–6)
Esomeprazole 40 0.26 (0.19–0.34) 4 (3–5)
Acid regurgitation Esomeprazole 20 0.18 (0.09–0.26) 6 (4–11)
Esomeprazole 40 0.20 (0.12–0.28) 5 (4–8)
PLUTO/VENUS (placebo) Heartburn Esomeprazole 20 0.23 (0.13–0.34) 4 (3–8)
Esomeprazole 40 0.28 (0.18–0.38) 4 (3–6)
Acid regurgitation Esomeprazole 20 0.2 (0.08–0.31) 5 (3–12)
Esomeprazole 40 0.2 (0.09–0.32) 5 (3–11)
285 (ranitidine) Heartburn Esomeprazole 20 0.17 (0.03–0.31) 6 (3–32)
Esomeprazole 40 0.15 (0.01–0.29) 7 (3–188)
Acid regurgitation Esomeprazole 20 0.2 (0.06–0.35) 5 (3–18)
Esomeprazole 40 0.17 (0.01–0.32) 6 (3–79)
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Thus, the maximum efficacy appears to have been
achieved with the 20-mg dose of esomeprazole.
In conclusion, in three patient populations repre-
senting the spectrum of continuous NSAID users, eso-
meprazole provided resolution of heartburn and acid
regurgitation. Therefore, our results add to the evidence
supporting the use of esomeprazole therapy for relief
of these symptoms in patients receiving continuous
NSAID therapy, including COX-2-selective agents.
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